Loading clinical trials...
Loading clinical trials...
A Phase 3 Study to Compare the Efficacy and Safety of Humacyte's Human Acellular Vessel With That of an Autologous Arteriovenous Fistula in Subjects With End Stage Renal Disease
The main purpose of this study is to compare the Human Acellular Vessel (HAV) with arteriovenous fistula (AVF) when used for hemodialysis access
This is a Phase 3, prospective, multicenter, open-label, randomized, two-arm, comparative study. Subjects who sign informed consent will undergo study-specific screening assessments within 45 days from the day of informed consent. Eligible study subjects will be randomized to receive either an HAV or AVF. The randomization will be stratified by upper arm or forearm placement based on the investigator's determination of where the study access (SA) should be located. Subjects will be followed to 24 months post SA creation at routine study visits regardless of patency status. After 24 months, AVF subjects with a patent SA will be followed (while the SA remains patent) for up to 5 years (60 months) post SA creation at routine study visits. After 24 months, HAV subjects will be followed (regardless of SA patency) for 5 years (60 months) post SA creation at routine study visits.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Arizona Kidney Disease and Hypertension Center (AKDHC)
Phoenix, Arizona, United States
University of Arizona
Tucson, Arizona, United States
University of California, Irvine
Irvine, California, United States
University of California San Diego, Jacobs Medical Center
La Jolla, California, United States
University of CA, San Diego - LaJolla VA Hospital
La Jolla, California, United States
Alliance Research
Laguna Hills, California, United States
VA Long Beach Healthcare System
Long Beach, California, United States
University of Southern California
Los Angeles, California, United States
Huntington Hospital
Pasadena, California, United States
UC Davis
Sacramento, California, United States
Start Date
September 29, 2017
Primary Completion Date
April 22, 2024
Completion Date
June 19, 2025
Last Updated
November 20, 2025
242
ACTUAL participants
Human Acellular Vessel (HAV)
BIOLOGICAL
Arteriovenous fistula (AVF)
PROCEDURE
Hemodialysis
OTHER
Lead Sponsor
Humacyte, Inc.
Collaborators
NCT07462741
NCT07146854
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT04163614